TRLV

Trulieve Cannabis Corp.

NYSEUSDEQUITY DELAYED

11.03

▲ 0.78 (7.61%)

MARKET · —

Price

Open

10.30

Prev close

10.25

Day high

11.17

Day low

10.24

Volume

1.55M

Market cap

—

P/E (TTM)

—

52W range

4.62 – 13.28

Trailing performance

Price return · vs SPY

Returnvs SPY

+15.03% +16.4%

+29.82% +26.1%

+40.86% +37.8%

+78.46% +67.4%

YTD

+27.73% +15.4%

+46.44% +26.4%

+192.88% +118.7%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

9.73

+13.31% from price

SMA 20

9.15

+21.34% from price

SMA 50

9.14

+21.43% from price

SMA 100

8.72

+26.47% from price

SMA 200

7.83

+41.74% from price

EMA 12

9.74

+13.22% from price

EMA 26

9.35

+18.01% from price

EMA 50

9.12

+20.90% from price

RSI (14)

71.9

Overbought

MACD (12,26,9)

0.39

Hist 0.22

ATR (14)

0.57

5.12% of price

Realised vol 30D

54.5%

Annualised

Bollinger upper

10.63

20, 2σ

Bollinger lower

7.67

20, 2σ

50 / 200 cross

Golden

9.14 vs 7.83

Trend bias

Above 200

+41.74%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.01

More volatile than market

Correlation to SPY

0.11

Largely independent

Realised vol 30D

54.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-54.4%

Peak to trough

Max drawdown 5Y

-89.6%

Peak to trough

ATR 14

0.57

5.12% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 11.03

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

TRLV · links out to the publisher

Happy Health Raises $75 Million for Healthcare in the Home: NYSE Content Update CNW Group · 4d ago Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE CNW Group · 4d ago Trulieve Completes Redomicile from British Columbia to Delaware PR Newswire · 11d ago Trulieve Cannabis Q2 Earnings Call Highlights MarketBeat · 13d ago Trulieve Cannabis (TRLV) Reports Steeper Losses And Lower Sales, Is The Valuation Discount Justified? Simply Wall St. · 15d ago Trulieve Shares Advance After Earnings Beat Despite Revenue Miss InvestorsHub · 15d ago Trulieve Cannabis Swings to Q2 Adjusted Earnings, Revenue Falls MT Newswires · 15d ago Trulieve: Q2 Earnings Snapshot Associated Press · 15d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.